Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Price Target at $16.75

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLDGet Free Report) have been assigned an average recommendation of “Moderate Buy” from the nine brokerages that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $16.75.

FOLD has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. JPMorgan Chase & Co. boosted their price objective on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Morgan Stanley reiterated an “equal weight” rating and issued a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Wells Fargo & Company decreased their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th.

Get Our Latest Report on Amicus Therapeutics

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FOLD. Wellington Management Group LLP lifted its holdings in Amicus Therapeutics by 18.8% in the 4th quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company’s stock valued at $268,112,000 after purchasing an additional 4,497,950 shares in the last quarter. Vestal Point Capital LP purchased a new position in Amicus Therapeutics in the 4th quarter valued at about $31,557,000. Norges Bank purchased a new position in Amicus Therapeutics in the 4th quarter valued at about $29,033,000. Orbimed Advisors LLC lifted its holdings in Amicus Therapeutics by 300.7% in the 4th quarter. Orbimed Advisors LLC now owns 2,285,400 shares of the biopharmaceutical company’s stock valued at $21,528,000 after purchasing an additional 1,715,100 shares in the last quarter. Finally, Rock Springs Capital Management LP lifted its holdings in Amicus Therapeutics by 107.9% in the 4th quarter. Rock Springs Capital Management LP now owns 2,599,425 shares of the biopharmaceutical company’s stock valued at $24,487,000 after purchasing an additional 1,349,145 shares in the last quarter.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD opened at $8.86 on Thursday. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. Amicus Therapeutics has a fifty-two week low of $8.78 and a fifty-two week high of $12.65. The stock has a market cap of $2.72 billion, a PE ratio of -49.22, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. The firm’s fifty day simple moving average is $9.43 and its 200-day simple moving average is $10.25.

Amicus Therapeutics Company Profile

(Get Free Report

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

Recommended Stories

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.